Skip to content

Effect of Deksmedetomidine and Remifentanil in Extubation Agitation

The Effect of Deksmedetomidin and Remifentanil Infusion on Extubation Agitation and Recovery Conditions on Nasal Septoplasty Operation

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02104297
Acronym
EA
Enrollment
90
Registered
2014-04-04
Start date
2014-04-30
Completion date
2014-06-30
Last updated
2014-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Agitation

Keywords

Nasal septum operation, agitation

Brief summary

To compare the effect of two different agents deksmedetomidine, remifentanil and placebo, agitation and recovery condition, on nasal septum operation.

Detailed description

Nasal septum operation cause agitation because of nasal package. This research aims determine which agent , deksmedetomidine remifentanil or placebo, is more beneficial to the patient.

Interventions

DRUGdeksmedetomidine

deksmedetomidine infused during operation 0.2 mcg/kg/hour

DRUGRemifentanil

Remifentanil infused during operation 0.2 mcg/kg/min

DRUGSaline

During operation saline infused equal volüme of deksmedetomidine and remifentanil

Sponsors

Diskapi Yildirim Beyazit Education and Research Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult patients

Exclusion criteria

* patients with any sensitivity each drug

Design outcomes

Primary

MeasureTime frame
To asses postoperative agitation score by Riker sedation agitation scalePostoperative first hour

Secondary

MeasureTime frame
Yo asses postoperative side effects emesis, vomitting or painPostoperative first hour

Countries

Turkey (Türkiye)

Contacts

Primary ContactReyhan Polat, MD
reyhanp9@gmail.com+905326734310

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026